×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RGLS – regulus therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RGLS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/11
08:09 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/7
04:05 pm
rgls
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
Neutral
Report
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
10/30
09:25 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
10/29
06:04 am
rgls
These 2 ‘Strong Buy' Penny Stocks Could Rally Over 500%, Say Analysts [Yahoo! Finance]
Medium
Report
These 2 ‘Strong Buy' Penny Stocks Could Rally Over 500%, Say Analysts [Yahoo! Finance]
10/8
03:48 pm
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
10/8
08:00 am
rgls
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
High
Report
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
9/17
05:31 am
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) was upgraded by analysts at StockNews.com to a "sell" rating.
9/6
11:07 pm
rgls
Regulus Therapeutics Inc. (NASDAQ: RGLS) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
Regulus Therapeutics Inc. (NASDAQ: RGLS) was upgraded by analysts at StockNews.com to a "sell" rating.
Date
Time
Symbol
Headline
Impact
11/14
05:46 pm
rgls
Form SC 13G/A Regulus Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Medium
Report
Form SC 13G/A Regulus Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
11/14
04:32 pm
rgls
Form SC 13G/A Regulus Therapeutics Filed by: BIOTECHNOLOGY VALUE FUND L P
Low
Report
Form SC 13G/A Regulus Therapeutics Filed by: BIOTECHNOLOGY VALUE FUND L P
11/14
02:36 pm
rgls
Form SC 13G/A Regulus Therapeutics Filed by: DAFNA Capital Management LLC
Low
Report
Form SC 13G/A Regulus Therapeutics Filed by: DAFNA Capital Management LLC
11/12
04:45 pm
rgls
Form SC 13G/A Regulus Therapeutics Filed by: VANGUARD GROUP INC
Medium
Report
Form SC 13G/A Regulus Therapeutics Filed by: VANGUARD GROUP INC
11/8
02:20 pm
rgls
Form SC 13G Regulus Therapeutics Filed by: BlackRock, Inc.
Low
Report
Form SC 13G Regulus Therapeutics Filed by: BlackRock, Inc.
11/7
04:29 pm
rgls
Form 10-Q Regulus Therapeutics For: Sep 30
Low
Report
Form 10-Q Regulus Therapeutics For: Sep 30
11/7
04:18 pm
rgls
Form 8-K Regulus Therapeutics For: Nov 07
Low
Report
Form 8-K Regulus Therapeutics For: Nov 07
11/4
01:47 pm
rgls
Form SC 13G/A Regulus Therapeutics Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Regulus Therapeutics Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/26
Form 4 Regulus Therapeutics For: Dec 24 Filed by: BASKETT FOREST
20.0%
6/17 Form PRE 14A Regulus Therapeutics For: Aug 01 19.4%
5/6 Regulus Therapeutics Announces Private Placement of Equity 17.8%
9/6 Regulus Therapeutics Inc (NASDAQ: RGLS) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 12.5%
1/3 Form 8-K Regulus Therapeutics For: Jan 03 11.9%
7/1 Form DEF 14A Regulus Therapeutics For: Aug 01 10.4%
5/21 Form 4/A Regulus Therapeutics For: May 07 Filed by: Witz Pascale 7.6%
8/6 Form 8-K Regulus Therapeutics For: Aug 01 6.9%
5/17 Form 8-K Regulus Therapeutics For: May 14 6.7%
5/9 Q1/2019 3/31/2019 EPS -0.310 ZacksConsensus -1.360 ActVsEst 1.050 - Beat 6.4%
6/17 Form PRE 14A Regulus Therapeutics For: Aug 01 19.4%
5/6 Regulus Therapeutics Announces Private Placement of Equity 17.8%
9/6 Regulus Therapeutics Inc (NASDAQ: RGLS) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 12.5%
1/3 Form 8-K Regulus Therapeutics For: Jan 03 11.9%
7/1 Form DEF 14A Regulus Therapeutics For: Aug 01 10.4%
5/21 Form 4/A Regulus Therapeutics For: May 07 Filed by: Witz Pascale 7.6%
8/6 Form 8-K Regulus Therapeutics For: Aug 01 6.9%
5/17 Form 8-K Regulus Therapeutics For: May 14 6.7%
5/9 Q1/2019 3/31/2019 EPS -0.310 ZacksConsensus -1.360 ActVsEst 1.050 - Beat 6.4%
TOP News Decliners
7/23
Regulus Therapeutics Announces RGLS4326 Program Update
-34.8%
1/9 Regulus Therapeutics Inc (NASDAQ: RGLS) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -24.4%
12/17 Regulus Therapeutics Inc (NASDAQ: RGLS) had its "hold" rating re-affirmed by analysts at Wedbush. They now have a $1.00 price target on the stock. -23.5%
8/8 Q2/2019 6/30/2019 EPS -0.300 ZacksConsensus -0.600 ActVsEst 0.300 - Beat -17.6%
5/10 Form 10-Q Regulus Therapeutics For: Mar 31 -13.6%
7/30 Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer -12.8%
3/11 Regulus Therapeutics Inc (NASDAQ: RGLS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -11.7%
10/20 Regulus Therapeutics Inc (NASDAQ: RGLS) was given a new $1.00 price target on by analysts at Wedbush. They now have a "hold" rating on the stock. -11.7%
1/24 Form 4 Regulus Therapeutics For: Jan 22 Filed by: Aker Christopher Ray -11.1%
6/5 Form S-3 Regulus Therapeutics -10.6%
1/9 Regulus Therapeutics Inc (NASDAQ: RGLS) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -24.4%
12/17 Regulus Therapeutics Inc (NASDAQ: RGLS) had its "hold" rating re-affirmed by analysts at Wedbush. They now have a $1.00 price target on the stock. -23.5%
8/8 Q2/2019 6/30/2019 EPS -0.300 ZacksConsensus -0.600 ActVsEst 0.300 - Beat -17.6%
5/10 Form 10-Q Regulus Therapeutics For: Mar 31 -13.6%
7/30 Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer -12.8%
3/11 Regulus Therapeutics Inc (NASDAQ: RGLS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -11.7%
10/20 Regulus Therapeutics Inc (NASDAQ: RGLS) was given a new $1.00 price target on by analysts at Wedbush. They now have a "hold" rating on the stock. -11.7%
1/24 Form 4 Regulus Therapeutics For: Jan 22 Filed by: Aker Christopher Ray -11.1%
6/5 Form S-3 Regulus Therapeutics -10.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: